Polytetrafluoroethylene-covered nitinol stent-graft for transjugular intrahepatic portosystemic shunt creation: 3-year experience

被引:107
作者
Rossi, P
Salvatori, FM
Fanelli, F
Bezzi, M
Rossi, M
Marcelli, G
Pepino, D
Riggio, O
Passariello, R
机构
[1] Policlin Umberto 1, Dept Radiol Sci, I-00161 Rome, Italy
[2] Policlin Umberto 1, Dept Gastroenterol, I-00161 Rome, Italy
关键词
hypertension; portal; liver; interventional procedures; shunts; portosystemic; stents and prostheses; venography;
D O I
10.1148/radiol.2313030349
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
PURPOSE: To prospectively evaluate the use of a recently developed expanded polytetrafluoroethylene (PTFE)-covered nitinol stent-graft in preventing the need for repeated intervention after transjugular intrahepatic portosystemic shunt (TIPS) creation. MATERIALS AND METHODS: Fifty-three consecutive patients underwent TIPS procedures between January 2000 and February 2002. Minimum patient follow-up was 9 months (mean, 16.3 months). Fifty-six stent-grafts were implanted in 53 patients; eight of the devices were 8 mm in diameter and 48 were 10 mm in diameter. The stent length varied from 4 to 7 cm. Indications for the procedure included recurrence of bleeding after sclerotherapy (28 patients with cirrhosis, one patient without), refractory ascites or hydrothorax (21 patients with cirrhosis, one patient without), and Budd-Chiari syndrome (two patients). RESULTS: A technical success rate of 100% was obtained, with an early clinical success rate of 96.2%. During the follow-up period, the recurrence rate was 3.4% (one of 29 patients) for bleeding and 9.0% (two of 22 patients) for ascites. Shunt malfunction occurred in nine of 53 patients (16.9%); in one of these nine patients, shunt occlusion was evident after revision, and a parallel shunt was created. The 1-year primary and secondary patency rates were 83.8% and 98.1%, respectively. In this series, the incidence of encephalopathy (included even as a single short-lived episode) was 47.1% (25 of 53 patients). The 30-day mortality rate was 3.8% (two of 53), and the late mortality rate was 17.3% (eight of 46), excluding seven patients who underwent transplantation. CONCLUSION: The new PTFE-covered nitinol stent-graft used appears to be excellent in preventing the need for repeated interventions. A primary patency rate of 83.8% and a secondary patency rate of 98.1% were achieved. (C) RSNA, 2004.
引用
收藏
页码:820 / 830
页数:11
相关论文
共 37 条
[11]   PORTAL PRESSURE, PRESENCE OF GASTROESOPHAGEAL VARICES AND VARICEAL BLEEDING [J].
GARCIATSAO, G ;
GROSZMANN, RJ ;
FISHER, RL ;
CONN, HO ;
ATTERBURY, CE ;
GLICKMAN, M .
HEPATOLOGY, 1985, 5 (03) :419-424
[12]  
Gerbes AL, 1998, Z GASTROENTEROL, V36, P373
[13]   HEMODYNAMIC EVENTS IN A PROSPECTIVE RANDOMIZED TRIAL OF PROPRANOLOL VERSUS PLACEBO IN THE PREVENTION OF A 1ST VARICEAL HEMORRHAGE [J].
GROSZMANN, RJ ;
BOSCH, J ;
GRACE, ND ;
CONN, HO ;
GARCIATSAO, G ;
NAVASA, M ;
ALBERTS, J ;
RODES, J ;
FISCHER, R ;
BERMANN, M ;
ROFE, S ;
PATRICK, M ;
LERNER, E .
GASTROENTEROLOGY, 1990, 99 (05) :1401-1407
[14]   Reporting standards for transjugular intrahepatic portosystemic shunts [J].
Haskal, ZJ ;
Rees, CR ;
Ring, EJ ;
Saxon, R ;
Sacks, D ;
Bakal, CW ;
Becker, GJ ;
Burke, DR ;
Cole, PE ;
Gray, RJ ;
Hansen, ME ;
Machan, LS ;
Martin, L ;
Marinelli, D ;
Patel, NH ;
ShlanskyGoldberg, R .
JOURNAL OF VASCULAR AND INTERVENTIONAL RADIOLOGY, 1997, 8 (02) :289-297
[15]   CREATION OF A STENOTIC STENT TO REDUCE FLOW-THROUGH A TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT [J].
HASKAL, ZJ ;
MIDDLEBROOK, MR .
JOURNAL OF VASCULAR AND INTERVENTIONAL RADIOLOGY, 1994, 5 (06) :827-829
[16]   PTFE-encapsulated endovascular stent-graft for transjugular intrahepatic portosystemic shunts: Experimental evaluation [J].
Haskal, ZJ ;
Davis, A ;
McAllister, A ;
Furth, EE .
RADIOLOGY, 1997, 205 (03) :682-688
[17]   Transjugular intrahepatic portosystemic shunts formed with polyethylene terephthalate-covered stents: Experimental evaluation in pigs [J].
Haskal, ZJ ;
Brennecke, LH .
RADIOLOGY, 1999, 213 (03) :853-859
[18]   Improved patency of transjugular intrahepatic portosystemic shunts in humans: Creation and revision with PTFE stent-grafts [J].
Haskal, ZJ .
RADIOLOGY, 1999, 213 (03) :759-766
[19]   Transjugular intrahepatic portosystemic shunt versus endoscopic sclerotherapy for the prevention of variceal bleeding in cirrhosis: A randomized multicenter trial [J].
Merli, M ;
Salerno, F ;
Riggio, O ;
de Franchis, R ;
Fiaccadori, F ;
Meddi, P ;
Primignani, M ;
Pedretti, G ;
Maggi, A ;
Capocaccia, L ;
Lovaria, A ;
Ugolotti, U ;
Salvatori, F ;
Bezzi, M ;
Rossi, P .
HEPATOLOGY, 1998, 27 (01) :48-53
[20]   IMPROVED TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT PATENCY WITH PTFE-COVERED STENT-GRAFTS - EXPERIMENTAL RESULTS IN SWINE [J].
NISHIMINE, K ;
SAXON, RR ;
KICHIKAWA, K ;
MENDELHARTVIG, J ;
TIMMERMANS, HA ;
SHIM, HJ ;
UCHIDA, BT ;
BARTON, RE ;
KELLER, FS ;
ROSCH, J .
RADIOLOGY, 1995, 196 (02) :341-347